{"entity":{"id":"nice-guidance","kind":"collection","name":"NICE cancer guidance and technology appraisals (UK)","aka":[],"tldr":"NICE decides which cancer treatments the NHS pays for, publishing for each drug an appraisal of cost per quality-adjusted life year against a threshold of £25,000 to £35,000, plus clinical guidelines. Because the manufacturer models and committee reasoning are public, its decisions serve as an independent view of a drug's value that often diverges from FDA and EMA licensing.","summary":"NICE technology appraisals (since 1999) assess clinical and cost-effectiveness against a threshold of £25,000-35,000 per QALY since 2 April 2026, raised from £20,000-30,000 (with severity modifiers, which replaced the end-of-life rule in 2022), and can recommend, restrict, or route drugs to the Cancer Drugs Fund for data collection. Clinical guidelines (e.g. NG12 suspected cancer recognition and referral) set diagnostic pathways. Appraisal documents contain manufacturer models, evidence review group critiques and committee reasoning, making them one of the most transparent public sources on drug value; decisions often diverge from FDA/EMA licensing.","asOf":"2026-09-08","links":[{"label":"NICE cancer topic page","url":"https://www.nice.org.uk/guidance/conditions-and-diseases/cancer"}],"tags":["gap-fill","guidelines"],"related":["nccn","esmo-guidelines"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":["drug-price-transparency","hazard-ratio","os","pfs"],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"url":"https://www.nice.org.uk/guidance/conditions-and-diseases/cancer","holds":"UK clinical guidelines (NG series), technology appraisals with cost-effectiveness decisions for every new cancer drug (including Cancer Drugs Fund managed access), quality standards and pathways.","license":"Open Government Licence / NICE terms","maintainer":"National Institute for Health and Care Excellence"},"route":"/collections/nice-guidance/","neighbours":{"collection":[{"id":"asco-guidelines","kind":"collection","name":"ASCO clinical practice guidelines","route":"/collections/asco-guidelines/"},{"id":"esmo-guidelines","kind":"collection","name":"ESMO Clinical Practice Guidelines & MCBS","route":"/collections/esmo-guidelines/"},{"id":"nccn","kind":"collection","name":"NCCN Guidelines","route":"/collections/nccn/"}],"term":[{"id":"cancer-drugs-fund","kind":"term","name":"Cancer Drugs Fund (England)","route":"/terms/cancer-drugs-fund/"},{"id":"hazard-ratio","kind":"term","name":"Hazard ratio (HR)","route":"/terms/hazard-ratio/"},{"id":"hta","kind":"term","name":"Health technology assessment (HTA), reimbursement and QALYs","route":"/terms/hta/"},{"id":"ilap","kind":"term","name":"ILAP (Innovative Licensing and Access Pathway)","route":"/terms/ilap/"},{"id":"innovative-medicines-fund","kind":"term","name":"Innovative Medicines Fund (England)","route":"/terms/innovative-medicines-fund/"},{"id":"nice-methods","kind":"term","name":"NICE technology appraisal methods (2022)","route":"/terms/nice-methods/"},{"id":"drug-price-transparency","kind":"term","name":"Oncology drug pricing and price transparency","route":"/terms/drug-price-transparency/"},{"id":"os","kind":"term","name":"Overall survival (OS)","route":"/terms/os/"},{"id":"pfs","kind":"term","name":"Progression-free survival (PFS)","route":"/terms/pfs/"}],"institution":[{"id":"nice","kind":"institution","name":"National Institute for Health and Care Excellence","route":"/institutions/nice/"}],"roadmap":[{"id":"global-access-roadmap","kind":"roadmap","name":"Global access and affordability roadmap: essential medicines and generics → biosimilars and frugal trials → reliance, pooling and homegrown innovation","route":"/roadmaps/global-access-roadmap/"}]}}